Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
BioFlorida ConferenceBioFlorida Conference
Not Confirmed
Not Confirmed
18-20 November, 2024
Not Confirmed
Not Confirmed
19-21 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
BioFlorida ConferenceBioFlorida Conference
Industry Trade Show
Not Confirmed
18-20 November, 2024
Industry Trade Show
Not Confirmed
19-21 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/medical-breakthroughs-in-2024-alzheimer-s-schizophrenia-copd-mash-see-pathbreaking-treatments
13 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/13/2980196/0/en/Clene-Reports-Third-Quarter-2024-Financial-Results-and-Recent-Operating-Highlights.html
09 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com//en/news-release/2024/10/09/2960462/0/en/Clene-to-Present-at-Upcoming-October-Conferences.html
01 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com//en/news-release/2024/10/01/2956564/0/en/Clene-Announces-Closing-of-7-3-Million-Registered-Direct-Offering-and-Concurrent-Private-Placements-and-Amendment-of-Debt-Facility.html
16 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/16/2946634/0/en/Clene-Granted-In-Person-Meeting-With-FDA-Senior-Leadership-to-Discuss-CNM-Au8-Biomarker-and-Related-Clinical-and-Survival-Data.html
07 Aug 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/08/07/2925929/0/en/Clene-Reports-Second-Quarter-2024-Financial-Results-and-Recent-Operating-Highlights.html
06 Aug 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/08/06/2925016/0/en/Clene-Announces-New-CNM-Au8-Biomarker-and-Clinical-Efficacy-Data-Submitted-to-FDA-In-Support-of-Treatment-For-ALS.html
Details:
The proceeds will be used to file a new drug application under the accelerated approval pathway for CNM-Au8, a catalytically active gold nanocrystal suspension.
Lead Product(s): CNM-Au8
Therapeutic Area: Neurology Brand Name: CNM-Au8
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: SymBiosis
Deal Size: $7.3 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 01, 2024
Lead Product(s) : CNM-Au8
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : SymBiosis
Deal Size : $7.3 million
Deal Type : Public Offering
Clene Closes $7.3M Offering and Amends Debt Facility for Ongoing Initiatives
Details : The proceeds will be used to file a new drug application under the accelerated approval pathway for CNM-Au8, a catalytically active gold nanocrystal suspension.
Brand Name : CNM-Au8
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 01, 2024
Details:
CNM-Au8 is a catalytically-active gold nanocrystal neuroprotective agent that enhances intracellular energy metabolism, in development for amyotrophic lateral sclerosis.
Lead Product(s): CNM-Au8
Therapeutic Area: Neurology Brand Name: CNM-Au8
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2024
Lead Product(s) : CNM-Au8
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Clene Granted Meeting with FDA to Discuss CNM-Au8 Biomarker Data
Details : CNM-Au8 is a catalytically-active gold nanocrystal neuroprotective agent that enhances intracellular energy metabolism, in development for amyotrophic lateral sclerosis.
Brand Name : CNM-Au8
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 16, 2024
Details:
CNM-Au8 is a catalytically-active gold nanocrystal neuroprotective agent that enhances intracellular energy metabolism, in development for amyotrophic lateral sclerosis.
Lead Product(s): CNM-Au8
Therapeutic Area: Neurology Brand Name: CNM-Au8
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 06, 2024
Lead Product(s) : CNM-Au8
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Clene Submits New Biomarker and Clinical Efficacy Data for CNM-Au8® in ALS
Details : CNM-Au8 is a catalytically-active gold nanocrystal neuroprotective agent that enhances intracellular energy metabolism, in development for amyotrophic lateral sclerosis.
Brand Name : CNM-Au8
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 06, 2024
Details:
CNM-Au8 is a catalytically-active gold nanocrystal neuroprotective agent that enhances intracellular energy metabolism, in development for amyotrophic lateral sclerosis.
Lead Product(s): CNM-Au8
Therapeutic Area: Neurology Brand Name: CNM-Au8
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: NIH
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2024
Lead Product(s) : CNM-Au8
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : NIH
Deal Size : Not Applicable
Deal Type : Not Applicable
Clene Provides Update on its NIH-Funded Expanded Access Program for CNM-Au8® in ALS
Details : CNM-Au8 is a catalytically-active gold nanocrystal neuroprotective agent that enhances intracellular energy metabolism, in development for amyotrophic lateral sclerosis.
Brand Name : CNM-Au8
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 28, 2024
Details:
CNM-Au8 is a catalytically-active gold nanocrystal neuroprotective agent that enhances intracellular energy metabolism. It is in development for treating amyotrophic lateral sclerosis.
Lead Product(s): CNM-Au8
Therapeutic Area: Neurology Brand Name: CNM-Au8
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Lead Product(s) : CNM-Au8
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Clene Reports Survival Benefit with CNM-Au8® in ALS Compassionate Use
Details : CNM-Au8 is a catalytically-active gold nanocrystal neuroprotective agent that enhances intracellular energy metabolism. It is in development for treating amyotrophic lateral sclerosis.
Brand Name : CNM-Au8
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 22, 2024
Details:
CNM-Au8, an oral gold nanocrystal suspension, is designed to restore neuronal health by enhancing neuroprotection, remyelination, and neuronal resilience against disease-relevant stressors.
Lead Product(s): CNM-Au8
Therapeutic Area: Neurology Brand Name: CNM-Au8
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Clene Reports Improvement in Vision and Cognition with CNM-Au8® in VISIONARY-MS Trial
Details : CNM-Au8, an oral gold nanocrystal suspension, is designed to restore neuronal health by enhancing neuroprotection, remyelination, and neuronal resilience against disease-relevant stressors.
Brand Name : CNM-Au8
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 08, 2024
Details:
CNM-Au8 is a ROS inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of patients with amyotrophic lateral sclerosis.
Lead Product(s): CNM-Au8
Therapeutic Area: Neurology Brand Name: CNM-Au8
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Lead Product(s) : CNM-Au8
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CNM-Au8 is a ROS inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of patients with amyotrophic lateral sclerosis.
Brand Name : CNM-Au8
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 21, 2023
Details:
The funding will support an Expanded Access Protocol for the Company’s investigational drug, CNM-Au8, an investigational first-in-class therapy, in amyotrophic lateral sclerosis (ALS).
Lead Product(s): CNM-Au8
Therapeutic Area: Neurology Brand Name: CNM-Au8
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: National Institute of Neurological Disorders and Stroke
Deal Size: $45.1 million Upfront Cash: Undisclosed
Deal Type: Funding October 05, 2023
Lead Product(s) : CNM-Au8
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : National Institute of Neurological Disorders and Stroke
Deal Size : $45.1 million
Deal Type : Funding
National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS
Details : The funding will support an Expanded Access Protocol for the Company’s investigational drug, CNM-Au8, an investigational first-in-class therapy, in amyotrophic lateral sclerosis (ALS).
Brand Name : CNM-Au8
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 05, 2023
Details:
CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors.
Lead Product(s): CNM-Au8
Therapeutic Area: Neurology Brand Name: CNM-Au8
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2023
Lead Product(s) : CNM-Au8
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant st...
Brand Name : CNM-Au8
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 25, 2023
Details:
CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors.
Lead Product(s): CNM-Au8
Therapeutic Area: Neurology Brand Name: CNM-Au8
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2023
Lead Product(s) : CNM-Au8
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant st...
Brand Name : CNM-Au8
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 29, 2023
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?